Moody Aldrich Partners LLC increased its position in Cambrex Corp. (NYSE:CBM) by 20.6% during the second quarter, Holdings Channel reports. The firm owned 24,285 shares of the company’s stock after buying an additional 4,155 shares during the period. Moody Aldrich Partners LLC owned approximately 0.08% of Cambrex Corp. worth $1,256,000 at the end of the most recent quarter.
Other institutional investors also recently modified their holdings of the company. Acadian Asset Management LLC raised its position in shares of Cambrex Corp. by 4.9% in the second quarter. Acadian Asset Management LLC now owns 1,303,496 shares of the company’s stock worth $67,426,000 after buying an additional 60,909 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in shares of Cambrex Corp. by 0.3% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 812,239 shares of the company’s stock worth $35,739,000 after buying an additional 2,588 shares during the period. Loomis Sayles & Co. L P raised its position in shares of Cambrex Corp. by 6.1% in the first quarter. Loomis Sayles & Co. L P now owns 428,046 shares of the company’s stock worth $18,834,000 after buying an additional 24,763 shares during the period. Panagora Asset Management Inc. raised its position in shares of Cambrex Corp. by 6.6% in the first quarter. Panagora Asset Management Inc. now owns 372,089 shares of the company’s stock worth $16,372,000 after buying an additional 23,121 shares during the period. Finally, Apex Capital Management raised its position in shares of Cambrex Corp. by 19.8% in the first quarter. Apex Capital Management now owns 342,019 shares of the company’s stock worth $15,049,000 after buying an additional 56,443 shares during the period. 99.46% of the stock is currently owned by institutional investors and hedge funds.
Shares of Cambrex Corp. (NYSE:CBM) traded up 0.65% during trading on Friday, reaching $46.60. 397,104 shares of the company traded hands. Cambrex Corp. has a 52 week low of $29.50 and a 52 week high of $59.41. The firm’s 50 day moving average price is $45.44 and its 200-day moving average price is $47.51. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of 23.56 and a beta of 1.45.
Cambrex Corp. (NYSE:CBM) last announced its quarterly earnings data on Thursday, July 28th. The company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.09. Cambrex Corp. had a net margin of 13.97% and a return on equity of 24.86%. The company earned $118.22 million during the quarter, compared to analysts’ expectations of $114.85 million. During the same quarter in the prior year, the company earned $0.63 EPS. Cambrex Corp.’s revenue was up 10.9% compared to the same quarter last year. Equities analysts anticipate that Cambrex Corp. will post $2.56 EPS for the current fiscal year.
Separately, Zacks Investment Research raised shares of Cambrex Corp. from a “hold” rating to a “strong-buy” rating and set a $55.00 target price on the stock in a research report on Wednesday, August 3rd.
In related news, Director William B. Korb sold 3,420 shares of the company’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $55.00, for a total transaction of $188,100.00. Following the completion of the sale, the director now owns 23,982 shares of the company’s stock, valued at approximately $1,319,010. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 2.63% of the company’s stock.
About Cambrex Corp.
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corp. (NYSE:CBM).
Receive News & Ratings for Cambrex Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corp. and related companies with MarketBeat.com's FREE daily email newsletter.